

Preclinical study of IOH-001, a Bispecific Antibody immunotherapy targeting PD-L1 and CD47

ImmuneOncia Therapeutics



ONCOLOGY	Non-Clinical
Product Type	Bispecific antibody
Indication	Breast Cancer
Target	PD-L1 and CD47
MoA(Mechanism of Action)	IOH-001 has been shown to activate immune cells in tumor microenvironment by blocking PD-1/PD-L1 signals that inhibit cytotoxic T-cells, while also blocking interaction with CD47/SIRP α between cancer cells and macrophages. We have investigated whether IOH-001 inhibits tumor growth via co-targeting tumor cells.
Competitiveness	1)Potentially superior safety profile: Safe haematological profile due to cancer cell-specific binding and weak binding to RBCs 2)Excellent anticancer activity: Strongly suppresses tumor growth and has immunological memories against cancer
Development Stage	Non-Clinical
Route of Administration	Intravenous